Browse by Medical Category
Department of Radiation Oncology
Accepting New Patients
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
David Miyamoto, MD, PhD is an Assistant Professor of Radiation Oncology at Harvard Medical School, an attending radiation oncologist at the Massachusetts General Hospital (MGH), and a physician scientist in the MGH Center for Cancer Research. Dr. Miyamoto received his undergraduate degree in Chemistry from Harvard College, MD from Harvard Medical School, and PhD in Cell Biology from Harvard University. He completed an internship in Internal Medicine at the Brigham & Women's Hospital, and his residency in radiation oncology in the Harvard Radiation Oncology Program. Dr. Miyamoto is a board-certified radiation oncologist specializing in genitourinary malignancies who sees patients in the Bertucci Center for Genitourinary Cancers at the MGH Cancer Center and the MGH Department of Radiation Oncology. His research efforts focus on the development of novel biomarkers to guide prostate cancer therapy, and the development of sensitive microfluidic platforms for the molecular analysis of circulating tumor cells (CTCs). He has authored and co-authored more than 30 publications in peer-reviewed scientific journals including Science, Cell, and Cancer Discovery. His research has been supported by the Prostate Cancer Foundation, Department of Defense, National Cancer Institute, and the Dana Farber/Harvard Cancer Center.
View my most recent research
The Miyamoto laboratory focuses on the discovery and development of novel biomarkers to guide the personalized treatment of patients with prostate cancer. We focus on two general classes of biomarkers, namely those based on the molecular profiles of tumor biopsies, and those based on circulating tumors cells (CTCs) in the blood that can be sampled non-invasively and repeatedly. By analyzing these patient-derived specimens, we have identified new molecular predictors of response to therapy and potential mechanisms of treatment resistance. Our overall aim is to develop tools for “real-time precision medicine” to probe the molecular signatures of cancers as they evolve over time, and to guide the precise and rational selection of appropriate therapies for each individual patient with prostate cancer.
View my most recent publications at PubMed
Back to Top